Johnson & Johnson to Acquire Yellow Jersey Therapeutics

Numab Therapeutics AG (Numab), a clinical stage biotechnology company advancing a proprietary pipeline of immunology and oncology therapeutics, announces that the Company has entered into a definitive agreement whereby Johnson & Johnson (NYSE: JNJ) acquires Yellow Jersey Therapeutics (YJT), a wholly-owned subsidiary of Numab to be spun-off to Numab’s shareholders. YJT comprises all assets relating to NM26, an investigational first-in-class bi-specific antibody for the treatment of atopic dermatitis (AD) set to advance into Phase 2 clinical development. Under the terms of the acquisition, J&J will pay a purchase price of $1.25 billion in cash for YJT.

Read the full article: Johnson & Johnson to Acquire Yellow Jersey Therapeutics //

Source: https://www.globenewswire.com/news-release/2024/05/28/2888935/0/en/Numab-Therapeutics-Announces-Johnson-Johnson-to-Acquire-its-Wholly-Owned-Subsidiary-Yellow-Jersey-Therapeutics-Including-Rights-to-NM26-a-Bi-Specific-Antibody-for-the-Treatment-of-.html

Scroll to Top